Physician profile
David Levin
NPI 1326015199
$1,670.60
in general payments reported to CMS, 2019-2025
14 companies · $224 in 2025
The $224 reported for 2025 was less than what a typical Nephrology (Internal Medicine) provider received nationally (typical 2025 total: $311).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $10.92 · 2021: $19.69 · 2022: $224 · 2023: $669 · 2024: $524 · 2025: $224.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,401 · Education: $15.26.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,401.16 |
| Education | $15.26 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Astrazeneca Pharmaceuticals Lp | $282.13 | 2019-2023 | Farxiga, Lokelma |
| Nxstage Medical, INC. | $246.61 | 2022-2024 | |
| Mallinckrodt Hospital Products INC. | $152.28 | 2023 | Terlivaz |
| Bayer Healthcare Pharmaceuticals INC. | $150.00 | 2023 | |
| Ardelyx, INC. | $148.86 | 2025 | Xphozah 30 Mg |
| Medtronic, INC. | $144.85 | 2024 | Ellipsys Vascular Access System |
| Amgen INC. | $136.36 | 2024 | Tavneos |
| Novartis Pharmaceuticals Corporation | $135.22 | 2024-2025 | |
| Vifor Pharma, INC. | $125.00 | 2022 | |
| Aurinia Pharma U.S., INC. | $52.36 | 2021-2025 | Lupkynis |
| Fresenius USA Marketing, INC. | $33.39 | 2023 | Velphoro |
| Travere Therapeutics, INC. | $30.32 | 2023-2025 | Filspari |
| Genzyme Corporation | $19.62 | 2023 | |
| Calliditas Therapeutics US INC. | $13.60 | 2023 | Tarpeyo |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw David Levin listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.